Peer review reports
From: The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion
Original Submission |
26 Nov 2014 |
Submitted |
Original manuscript
|
|
Author responded |
Author comments
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
|
Author responded |
Author comments
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
|
Author responded |
Author comments
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
|
Author responded |
Author comments
|
|
Reviewed |
Reviewer Report
|
|
Reviewed |
Reviewer Report
|
Resubmission - Version 5 |
|
Submitted |
Manuscript version 5
|
|
Author responded |
Author comments
|
Resubmission - Version 6 |
|
Submitted |
Manuscript version 6
|
Publishing |
14 Jul 2015 |
Editorially accepted |
|
23 Jul 2015 |
Article published |
10.1186/s12885-015-1555-8
|
Learn about peer review